Acadia Pharmaceuticals (ACAD - Free Report) closed the last trading session at $24.96, gaining 6.9% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $32.67 indicates a 30.9% upside potential.
The mean estimate comprises 21 short-term price targets with a standard deviation of $6.14. While the lowest estimate of $17.00 indicates a 31.9% decline from the current price level, the most optimistic analyst expects the stock to surge 80.3% to reach $45.00. It's very important to note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts.
While the consensus price target is a much-coveted metric for investors, solely banking on this metric to make an investment decision may not be wise at all. That's because the ability and unbiasedness of analysts in setting price targets have long been questionable.
But, for ACAD, an impressive average price target is not the only indicator of a potential upside. Strong agreement among analysts about the company's ability to report better earnings than they predicted earlier strengthens this view. While a positive trend in earnings estimate revisions doesn't gauge how much a stock could gain, it has proven to be powerful in predicting an upside.
Price, Consensus and EPS Surprise
Here's What You May Not Know About Analysts' Price TargetsAccording to researchers at several universities across the globe, a price target is one of many pieces of information about a stock that misleads investors far more often than it guides. In fact, empirical research shows that price targets set by several analysts, irrespective of the extent of agreement, rarely indicate where the price of a stock could actually be heading.
While Wall Street analysts have deep knowledge of a company's fundamentals and the sensitivity of its business to economic and industry issues, many of them tend to set overly optimistic price targets. Are you wondering why?
They usually do that to drum up interest in shares of companies that their firms either have existing business relationships with or are looking to be associated with. In other words, business incentives of firms covering a stock often result in inflated price targets set by analysts.
However, a tight clustering of price targets, which is represented by a low standard deviation, indicates that analysts have a high degree of agreement about the direction and magnitude of a stock's price movement. While that doesn't necessarily mean the stock will hit the average price target, it could be a good starting point for further research aimed at identifying the potential fundamental driving forces.
That said, while investors should not entirely ignore price targets, making an investment decision solely based on them could lead to disappointing ROI. So, price targets should always be treated with a high degree of skepticism.
Here's Why There Could be Plenty of Upside Left in ACADThere has been increasing optimism among analysts lately about the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher. And that could be a legitimate reason to expect an upside in the stock. After all, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
Over the last 30 days, the Zacks Consensus Estimate for the current year has increased 3.9%, as two estimates have moved higher compared to no negative revision.
Moreover, ACAD currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than 4,000 stocks that we rank based on four factors related to earnings estimates. Given an impressive externally-audited track record, this is a more conclusive indication of the stock's potential upside in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Therefore, while the consensus price target may not be a reliable indicator of how much ACAD could gain, the direction of price movement it implies does appear to be a good guide.
Bessemer Group Inc. lifted its stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 21,126.8% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 150,498 shares of the biopharmaceutical company’s stock after buying an additional 149,789 shares during the period. Bessemer Group Inc. owned approximately 0.09% of ACADIA Pharmaceuticals worth $3,350,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Allspring Global Investments Holdings LLC boosted its stake in ACADIA Pharmaceuticals by 44.9% in the first quarter. Allspring Global Investments Holdings LLC now owns 954,855 shares of the biopharmaceutical company’s stock valued at $21,312,000 after acquiring an additional 296,042 shares in the last quarter. Illinois Municipal Retirement Fund grew its holdings in shares of ACADIA Pharmaceuticals by 12.7% during the first quarter. Illinois Municipal Retirement Fund now owns 71,183 shares of the biopharmaceutical company’s stock worth $1,585,000 after purchasing an additional 7,996 shares during the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management increased its position in shares of ACADIA Pharmaceuticals by 30.6% during the first quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 12,923 shares of the biopharmaceutical company’s stock worth $288,000 after purchasing an additional 3,026 shares in the last quarter. Principal Financial Group Inc. increased its position in shares of ACADIA Pharmaceuticals by 3.1% during the first quarter. Principal Financial Group Inc. now owns 768,224 shares of the biopharmaceutical company’s stock worth $17,101,000 after purchasing an additional 22,868 shares in the last quarter. Finally, Fifth Third Bancorp lifted its holdings in shares of ACADIA Pharmaceuticals by 5,053.5% in the 1st quarter. Fifth Third Bancorp now owns 31,694 shares of the biopharmaceutical company’s stock valued at $706,000 after purchasing an additional 31,079 shares during the last quarter. 96.71% of the stock is currently owned by institutional investors and hedge funds.
Insider Activity at ACADIA Pharmaceuticals In related news, insider James Kihara sold 5,401 shares of the stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $21.18, for a total transaction of $114,393.18. Following the completion of the sale, the insider directly owned 24,509 shares of the company’s stock, valued at $519,100.62. This trade represents a 18.06% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Mark C. Schneyer sold 3,506 shares of ACADIA Pharmaceuticals stock in a transaction on Monday, May 4th. The shares were sold at an average price of $21.79, for a total transaction of $76,395.74. Following the completion of the transaction, the executive vice president owned 66,145 shares in the company, valued at approximately $1,441,299.55. This trade represents a 5.03% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 10,239 shares of company stock valued at $219,813 in the last 90 days. Company insiders own 26.20% of the company’s stock.
ACADIA Pharmaceuticals Stock Up 1.4% NASDAQ ACAD opened at $25.43 on Wednesday. ACADIA Pharmaceuticals Inc. has a 52-week low of $19.69 and a 52-week high of $28.35. The business’s 50-day moving average price is $23.05 and its 200 day moving average price is $23.27. The firm has a market cap of $4.35 billion, a P/E ratio of 11.56, a P/E/G ratio of 18.07 and a beta of 0.80.
ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) last posted its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.04 by ($0.02). ACADIA Pharmaceuticals had a net margin of 34.30% and a return on equity of 9.61%. The company had revenue of $268.10 million for the quarter, compared to analysts’ expectations of $280.25 million. During the same period in the prior year, the company earned $0.11 earnings per share. The firm’s revenue was up 9.7% on a year-over-year basis. As a group, analysts anticipate that ACADIA Pharmaceuticals Inc. will post 0.37 earnings per share for the current year.
Wall Street Analyst Weigh In A number of brokerages recently issued reports on ACAD. Weiss Ratings cut ACADIA Pharmaceuticals from a “hold (c+)” rating to a “hold (c)” rating in a research report on Friday, May 1st. HC Wainwright lowered ACADIA Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, June 30th. Royal Bank Of Canada boosted their price objective on ACADIA Pharmaceuticals from $29.00 to $36.00 and gave the company an “outperform” rating in a research note on Tuesday, July 7th. Citigroup increased their price objective on ACADIA Pharmaceuticals from $32.00 to $35.00 and gave the company a “buy” rating in a report on Monday, June 29th. Finally, BMO Capital Markets raised their target price on shares of ACADIA Pharmaceuticals from $34.00 to $36.00 and gave the stock an “outperform” rating in a research report on Tuesday. Thirteen analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $33.17.
Check Out Our Latest Research Report on ACAD
About ACADIA Pharmaceuticals (Free Report)
ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.
The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.
See Also Five stocks we like better than ACADIA Pharmaceuticals Confidence Is Back, But Earnings Show the Consumer Is Being Picky AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off 3M’s Redemption Arc: Can Q2 Earnings Change the Narrative? 3 Photonics Companies Making Quantum Tech Possible
Receive News & Ratings for ACADIA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINED.A. Davidson & CO. Has $1.84 Million Holdings in Welltower Inc. $WELL
NEXT HEADLINE »Bessemer Group Inc. Purchases 529,678 Shares of Adamas Trust, Inc. $ADAM
Key Takeaways Acadia received FDA Fast Track designation for remlifanserin in Alzheimer's disease psychosis. ACAD expects phase II top-line data between September and October 2026 as phase III enrollment continues. Acadia expects Nuplazid and Daybue combined net sales of about $1.7 billion by 2028. Acadia Pharmaceuticals (ACAD - Free Report) announced that the FDA has granted Fast Track designation to its investigational, highly selective, 5-HT2A receptor inverse agonist, remlifanserin, for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP).
The FDA’s Fast Track designation is intended to expedite the development and review of drugs that treat serious conditions and fulfill unmet medical needs to get important new drugs to patients earlier. It offers benefits, such as more frequent FDA interactions, rolling submission of marketing applications and potential eligibility for Priority Review if certain conditions are met.
According to Acadia, there are currently no FDA-approved therapies for treating ADP.
More on ACAD’s RemlifanserinClinical Development ProgramAcadia is currently evaluating the safety and efficacy of remlifanserin in the RADIANT development program for the treatment of hallucinations and delusions associated with ADP. The company has completed enrollment in the phase II portion of the program and now expects to report top-line results between September and October 2026. Meanwhile, in line with the RADIANT program's seamless operational design, screening and patient enrollment are already underway for the phase III studies. In 2025, ACAD initiated another phase II study of remlifanserin for a second indication – Lewy Body Dementia with Psychosis.
Year to date, ACAD shares have lost 6% against the industry’s 2.4% growth.
Image Source: Zacks Investment Research
Apart from remlifanserin, Acadia’s clinical pipeline comprises several other candidates. The company, in partnership with Saniona, is gearing up to initiate a mid-stage study of ACP-711 for essential tremor in late 2026. In late 2025, ACAD initiated a mid-stage study of ACP-211 for the treatment of major depressive disorder. A first-in-human study of ACP-271 in healthy volunteers was also initiated in the first quarter of 2026.
ACAD's Marketed Drugs Expected to Aid GrowthAcadia’s long-term growth is supported by its lead product, Nuplazid and Daybue, in the United States. The company expects to generate around $1.7 billion in combined net sales by 2028, including $1 billion for Nuplazid and $700 million for Daybue.
Nuplazid is the first and only FDA-approved treatment for hallucinations and delusions associated with Parkinson’s disease psychosis in the United States. The drug enjoys patent protection in the United States until 2038, giving it a long runway for revenue generation by protecting against generic erosion. In the first quarter of 2026, Nuplazid recorded $167 million in sales, up 5% year over year, driven primarily by volume growth.
Since its U.S. launch in 2023 as the first and only treatment for Rett syndrome in adults and pediatric patients aged two years and older, Daybue has witnessed encouraging sales uptake. In the first quarter of 2026, Daybue recorded $101 million in sales, up 20% year over year, driven by growth in the drug’s unit sales as Acadia shipped it to more unique patients. A similar filing is also currently under regulatory review in the EU. A potential nod could further boost sales. Daybue is also marketed (and available) in Canada and Israel for the same indication.
In late 2025, the FDA approved Daybue Stix (trofinetide), a dye- and preservative-free powder formulation for the treatment of Rett syndrome in adults and pediatric patients aged two years and older. The new product expands the Daybue franchise, which remains the only FDA-approved treatment option for this indication.
Daybue Stix is now broadly available in the United States. The company will continue to offer the current oral solution alongside the new formulation, strengthening its positioning in the Rett syndrome treatment market.
ACAD's Zacks Rank & Stocks to ConsiderAcadia currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Neurocrine Biosciences (NBIX - Free Report) , Amarin Corporation (AMRN - Free Report) and Liquidia Corporation (LQDA - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Neurocrine Biosciences’ 2026 earnings per share have risen from $9.15 to $9.44. Over the same period, EPS estimates for 2027 have increased from $10.23 to $10.79. NBIX shares have gained 22% year to date.
Neurocrine Biosciences’ earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 9.08%.
Over the past 60 days, loss per share estimates for Amarin have narrowed from $6.36 to 65 cents for 2026. Over the same period, estimates for loss per share have also narrowed from $4.64 to 51 cents for 2027. AMRN shares have lost 2.5% year to date.
Amarin’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 50.02%.
Over the past 60 days, estimates for Liquidia’s 2026 earnings per share have increased to $3.02 from $2.97. Over the same period, EPS estimates for 2027 have risen to $4.92 from $4.81. LQDA shares have soared 123.5% year to date.
Liquidia’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 54.40%.
Allspring Global Investments Holdings LLC lifted its stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 44.9% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 954,855 shares of the biopharmaceutical company’s stock after buying an additional 296,042 shares during the quarter. Allspring Global Investments Holdings LLC owned approximately 0.56% of ACADIA Pharmaceuticals worth $21,312,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently modified their holdings of ACAD. Illinois Municipal Retirement Fund grew its stake in ACADIA Pharmaceuticals by 12.7% during the first quarter. Illinois Municipal Retirement Fund now owns 71,183 shares of the biopharmaceutical company’s stock valued at $1,585,000 after acquiring an additional 7,996 shares in the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management boosted its holdings in shares of ACADIA Pharmaceuticals by 30.6% during the 1st quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 12,923 shares of the biopharmaceutical company’s stock valued at $288,000 after purchasing an additional 3,026 shares during the last quarter. Principal Financial Group Inc. grew its position in shares of ACADIA Pharmaceuticals by 3.1% during the first quarter. Principal Financial Group Inc. now owns 768,224 shares of the biopharmaceutical company’s stock valued at $17,101,000 after purchasing an additional 22,868 shares in the last quarter. Fifth Third Bancorp grew its position in shares of ACADIA Pharmaceuticals by 5,053.5% during the first quarter. Fifth Third Bancorp now owns 31,694 shares of the biopharmaceutical company’s stock valued at $706,000 after purchasing an additional 31,079 shares in the last quarter. Finally, Hsbc Holdings PLC increased its holdings in shares of ACADIA Pharmaceuticals by 67.4% in the first quarter. Hsbc Holdings PLC now owns 44,008 shares of the biopharmaceutical company’s stock worth $977,000 after purchasing an additional 17,722 shares during the last quarter. Institutional investors own 96.71% of the company’s stock.
Wall Street Analysts Forecast Growth A number of equities research analysts recently commented on the company. Bank of America boosted their target price on ACADIA Pharmaceuticals from $29.00 to $30.00 and gave the stock a “buy” rating in a research report on Tuesday, June 30th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a $37.00 price target on shares of ACADIA Pharmaceuticals in a report on Monday, June 29th. Citigroup boosted their price objective on ACADIA Pharmaceuticals from $32.00 to $35.00 and gave the stock a “buy” rating in a research note on Monday, June 29th. Canaccord Genuity Group raised their price objective on ACADIA Pharmaceuticals from $32.00 to $36.00 and gave the company a “buy” rating in a research note on Monday, June 29th. Finally, Weiss Ratings cut ACADIA Pharmaceuticals from a “hold (c+)” rating to a “hold (c)” rating in a report on Friday, May 1st. Twelve research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $32.94.
View Our Latest Research Report on ACAD
ACADIA Pharmaceuticals Stock Performance Shares of NASDAQ ACAD opened at $25.09 on Tuesday. ACADIA Pharmaceuticals Inc. has a fifty-two week low of $19.69 and a fifty-two week high of $28.35. The company has a market cap of $4.30 billion, a price-to-earnings ratio of 11.40, a PEG ratio of 18.44 and a beta of 0.80. The business’s 50 day moving average price is $22.98 and its 200-day moving average price is $23.28.
ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) last posted its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported $0.02 EPS for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.02). The company had revenue of $268.10 million during the quarter, compared to the consensus estimate of $280.25 million. ACADIA Pharmaceuticals had a return on equity of 9.61% and a net margin of 34.30%.The company’s revenue for the quarter was up 9.7% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.11 earnings per share. Sell-side analysts predict that ACADIA Pharmaceuticals Inc. will post 0.37 earnings per share for the current year.
Insider Activity at ACADIA Pharmaceuticals In other news, insider James Kihara sold 5,401 shares of the stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $21.18, for a total transaction of $114,393.18. Following the transaction, the insider owned 24,509 shares of the company’s stock, valued at approximately $519,100.62. This represents a 18.06% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Mark C. Schneyer sold 3,506 shares of the firm’s stock in a transaction on Monday, May 4th. The shares were sold at an average price of $21.79, for a total value of $76,395.74. Following the transaction, the executive vice president owned 66,145 shares in the company, valued at approximately $1,441,299.55. This represents a 5.03% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 10,239 shares of company stock valued at $219,813 in the last ninety days. Insiders own 26.20% of the company’s stock.
ACADIA Pharmaceuticals Profile (Free Report)
ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.
The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.
Featured Stories Five stocks we like better than ACADIA Pharmaceuticals The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story
Receive News & Ratings for ACADIA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEAllspring Global Investments Holdings LLC Has $21.26 Million Position in ITT Inc. $ITT
NEXT HEADLINE »Allspring Global Investments Holdings LLC Reduces Stock Position in Sempra Energy $SRE
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to remlifanserin, an investigational, highly selective, 5-HT2A receptor inverse agonist, for the treatment of hallucinations and delusions associated with Alzheimer's disease psychosis (ADP). Fast Track designation is designed to facilitate the development and expedite the review of drugs intended to treat serious conditions a.
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report second quarter 2026 financial results on Tuesday, August 4, 2026, after the close of the U.S. financial markets. Acadia's management team will also host a conference call and webcast on August 4, 2026, at 4:30 p.m. Eastern Time. The conference call will be available on Acadia's website, acadia.com under the investors section and will be archived for approximately 90 days. The conference ca.
James Kihara, Principal Accounting Officer of Acadia Pharmaceuticals (ACAD 0.72%), disclosed the sale of 11,421 shares of common stock in an open-market transaction on June 26, 2026, according to the SEC Form 4 filing.
Transaction summaryMetricValueShares sold (direct)11,421Transaction value~$298,000Post-transaction shares (direct)13,088Post-transaction value (direct ownership)~$331,000Transaction value based on SEC Form 4 weighted average price ($26.08); post-transaction value based on June 26, 2026 market close price.
Key questionsHow does this transaction compare to prior open-market sales by James Kihara?
This 11,421-share sale is Kihara's largest single open-market sale on record, exceeding his previous sale on May 26, 2026 (5,401 shares), and surpassing the five-trade average of approximately 4,964 shares per sale.What proportion of Kihara's available direct shareholding was involved in this sale?
The transaction represented 46.60% of his direct holdings prior to the sale, a significant reduction that left only 13,088 shares directly held post-transaction.Were any derivative or indirect holdings involved in this disposition?
No derivative securities or indirect entities were involved; all shares sold were directly owned common stock, and no options or trust-held shares were reported in this filing.Does the cadence or scale of this sale reflect a change in disposition strategy?
Recent filings indicate an acceleration in selling as Kihara’s holdings have declined, with increasing sale sizes explained by the drawdown in available capacity rather than a discretionary slow-down or escalation.Company overviewMetricValueEmployees653Revenue (TTM)$1.10 billionNet income (TTM)$375.65 million1-year price change23.96%*1-year price change calculated as of June 26, 2026.
Company snapshotCore product: NUPLAZID (pimavanserin) for Parkinson's disease psychosis; pipeline includes late-stage candidates for Alzheimer's disease psychosis, Rett syndrome, and pain management.Revenue is primarily generated through the commercialization of proprietary therapeutics for central nervous system (CNS) disorders, with additional growth potential from clinical-stage assets.Target customers include neurologists, psychiatrists, and healthcare providers treating CNS disorders, with a focus on patients experiencing unmet medical needs.Acadia Pharmaceuticals is a biopharmaceutical company specializing in the discovery, development, and commercialization of innovative treatments for central nervous system disorders.
The company leverages its expertise in neuroscience to address significant gaps in the treatment landscape, with a marketed product and several late-stage pipeline candidates. Acadia’s strategic focus on high-need indications and a robust clinical pipeline position it as a differentiated player within the biotechnology sector.
What this transaction means for investorsThe June 26 sale of Acadia Pharmaceuticals stock by Principal Accounting Officer James Kihara is noteworthy for investors because it represented a substantial disposition of 46.6% of his holdings. The transaction came at a time when Acadia shares were soaring on the news that the European Medicines Agency recommended the company’s Daybue drug be allowed for sale in the European Union.
Kihara’s trade was at a weighted average price of $26.08 per share, close to the 52-week high of $28.35. While it seems he was capitalizing on the rising price, his sale was a non-discretionary transaction executed as part of a pre-established Rule 10b5-1 plan, adopted in December of 2025. Such plans enable insiders to sell shares at predetermined times to avoid concerns of trading on non-public information.
Even so, the fact that he disposed of nearly half his direct holdings is concerning, especially since the sale was about double his average transaction size. However, Acadia’s business is doing well. It kicked off 2026 with $268.1 million in first-quarter revenue, up from the prior year’s $244.3 million.
Robert Izquierdo has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Royalty Pharma (RPRX) and Acadia Pharmaceuticals (ACAD). But which of these two companies is the best option for those looking for undervalued stocks?
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Carl Segerstrom as Chief People Officer, effective July 6. Carl will lead the company's global people and culture strategy, supporting its next phase of growth as a leading neurological and rare disease company focused on advancing therapies for patients with significant unmet needs. He will serve as a member of Acadia's executive leadership team. “Carl is a proven global leader with a stro.
Key Takeaways ACAD up 6.8% after the CHMP recommended Daybu for EU approval in Rett syndrome following re-examination.Daybu could become the first EU-approved treatment for Rett syndrome's neurobehavioral symptoms.Acadia's phase III LAVENDER data supported the positive opinion after an earlier CHMP refusal. Acadia Pharmaceuticals (ACAD - Free Report) shares climbed 6.8% on Friday after the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion following a re-examination procedure, recommending the approval of Daybu (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. The recommendation marks a major regulatory turnaround for the therapy, which could become the first approved treatment for this indication in the EU.
The positive CHMP recommendation represents an important milestone for Acadia as it seeks to expand Daybu's commercial footprint. Rett syndrome is a rare neurodevelopmental disorder with no therapies currently approved in the EU specifically for its neurobehavioral symptoms, leaving patients with limited treatment options. An approval would allow Acadia to address a significant unmet medical need while strengthening the long-term growth prospects of its rare disease franchise.
The CHMP's favorable opinion was primarily supported by data from the pivotal phase III LAVENDER study, which demonstrated statistically significant and clinically meaningful improvements in key measures of Rett syndrome. The study met its co-primary endpoints, showing benefits on the Rett Syndrome Behavior Questionnaire and the Clinical Global Impression-Improvement scale, indicating that Daybu can improve some of the core neurobehavioral manifestations of the disease that substantially affect patients' daily functioning and caregiver burden.
Following the CHMP recommendation, the European Commission (EC) will review the agency's opinion before issuing a final regulatory decision, which is expected in the coming months. If approved, Daybu's centralized marketing authorization would be valid across all 27 EU member states as well as Iceland, Liechtenstein and Norway, significantly expanding access to the therapy across Europe.
The FDA approved trofinetide as the first and only treatment for Rett syndrome in adults and pediatric patients aged two years and older in 2023. The drug is marketed under the brand name Daybue in the United States. Daybue is also marketed (and available) in Canada and Israel for the same indication.
Year to date, Acadia shares have lost 5.2% against the industry’s 5.2% growth.
Image Source: Zacks Investment Research
Earlier CHMP Refusal Delayed EU Expansion of ACAD’s DaybuThe latest recommendation follows a significant regulatory setback earlier this year, when the CHMP formally adopted a negative opinion recommending against the approval of trofinetide for the treatment of Rett syndrome in patients aged two years and older in the EU. The decision came after the committee had previously notified Acadia of a negative trend vote on the marketing application in early February, prompting the company to seek a formal re-examination of the application.
Although the pivotal LAVENDER study had achieved its co-primary and key secondary endpoints, the CHMP had previously concluded that several aspects of the evidence package limited its ability to support approval. The committee viewed the treatment benefit observed after 12 weeks as modest, questioned whether the study adequately captured all core symptoms of Rett syndrome and expressed concerns that patient discontinuations may have affected the interpretation of longer-term outcomes.
Following the initial refusal, Acadia reviewed the CHMP's objections in detail and proceeded with the re-examination process, ultimately securing the positive recommendation now under consideration by the EC. The favorable outcome substantially improves the therapy's regulatory outlook in Europe and revives the company's efforts to bring Daybu to patients across the region.
ACAD's Marketed Drugs Expected to Aid GrowthAcadia’s long-term growth is supported by its lead product, Nuplazid and Daybue in the United States. The company expects to generate around $1.7 billion in combined net sales by 2028, including $1 billion for Nuplazid and $700 million for Daybue.
Nuplazid is the first and only FDA-approved treatment for hallucinations and delusions associated with Parkinson’s disease psychosis in the United States. The drug enjoys patent protection in the United States until 2038, which gives it a long runway for revenue generation by protecting against generic erosion. In the first quarter of 2026, Nuplazid recorded $167 million in sales, up 5% year over year, driven primarily by volume growth.
Since its launch in 2023, Daybue has witnessed encouraging sales uptake. In the first quarter of 2026, Daybue recorded $101 million in sales, up 20% year over year, driven by growth in the drug’s unit sales as Acadia shipped it to more unique patients. A potential EU approval could further boost sales.
In late 2025, the FDA approved Daybue Stix (trofinetide) for oral solution, a dye- and preservative-free powder formulation for the treatment of Rett syndrome in adults and pediatric patients aged two years and older. The new product expands the Daybue franchise, which remains the only FDA-approved treatment option for this indication.
Per Acadia, the full U.S. launch of Daybue STIX is underway, with nearly 30% of patients using STIX either new to treatment or resuming therapy after previously discontinuing the liquid formulation. The company will continue to offer both formulations in the United States, strengthening its positioning in the Rett syndrome treatment market.
ACAD's Zacks Rank & Stocks to ConsiderAcadia currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Liquidia Corporation (LQDA - Free Report) , Indivior Pharmaceuticals (INDV - Free Report) and Immunocore (IMCR - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Liquidia Corporation’s 2026 EPS have increased from $1.50 to $2.97. Over the same period, EPS estimates for 2027 have also increased from $2.91 to $4.81. LQDA shares have rallied 126.7% year to date.
Liquidia Corporation’searnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 54.40%.
Over the past 60 days, estimates for Indivior Pharmaceuticals’ 2026 earnings per share have increased from $3.34 to $4.05. Over the same period, EPS estimates for 2027 have risen to $4.27 from $3.56. INDV shares have gained 16.6% year to date.
Indivior Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 65.44%.
The estimate for Immunocore’s 2026 EPS is currently pegged at 6 cents. In the past 60 days, the estimates for its 2027 EPS have increased from 24 cents to 87 cents. IMCR shares have lost 11% year to date.
Immunocore’s earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average surprise being 46.66%.
Acadia (ACAD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
SummaryAcadia Pharmaceuticals demonstrates steady commercial growth with Nuplazid and Daybue, supported by a recent positive CHMP opinion for Daybue in Europe.Remlifanserin's upcoming phase 2 readout in Alzheimer's disease psychosis is a high-risk, high-reward catalyst not priced into ACAD's current valuation.I maintain a bullish outlook on ACAD based on commercial products Nuplazid and Daybue, but above-average returns depend on pipeline or business development success.ACAD's valuation remains below the combined Nuplazid and Daybue value, with $851M cash and positive cash flows supporting future pipeline expansion.Looking for more investing ideas like this one? Get them exclusively at Growth Stock Forum. Learn More »Sitewide Sale 2026: Get 20% Off BeritK/iStock via Getty Images
It has been more than a year since I last wrote about Acadia Pharmaceuticals (ACAD). Since then, we saw the failure of ACP-101 in Prader-Willi syndrome, which I wrote was a realistic possibility
9.58K Followers
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
This article reflects the author's opinion and should not be regarded as a buy or sell recommendation or investment advice in any way.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
Already recovering from weakness suffered early this year, Acadia Pharmaceuticals (ACAD +9.44%) shares were outright catapulted higher today. Indeed, the pharmaceutical stock's 12.2% gain as of 12:17 p.m. ET Friday has pushed it back within sight of its 52-week high hit late last year.
The prompt for this bullishness? Unsurprisingly, encouraging news regarding one of its two approved drugs.
A new market is about to open up With a market cap of less than $5 billion, Acadia is anything but a pharmaceutical powerhouse. But, it's not trying to be one. Its focus is relatively narrow, aimed at underserved rare conditions like neurological disorder Rett syndrome, or psychosis stemming from Parkinson's disease and Alzheimer's.
To this end, the company's only two treatments currently approved anywhere are Daybue (for Rett) and Nuplazid (for psychosis), which produced revenue of $101 million and $167 million -- respectively -- during the first fiscal quarter of this year.
Image source: Getty Images.
After growing 20% year over year in Q1, however, sales of Daybue could soon be even higher. On Friday, the company announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommends its approval in the EU as a treatment for the neurobehavioral symptoms of Rett syndrome. If ultimately approved, it would be the first treatment permitted in Europe for this particular purpose.
Just be patient It's unclear how big Europe's Rett syndrome market is, though given what's known about the U.S. market and Acadia's focus on rare diseases, it's presumably not enormous.
On the other hand, neither is Acadia Pharmaceuticals, and it faces little to no real competition on either front.
Acadia is also -- surprisingly enough for a pharma company of its size, age, and ilk -- profitable. It's testing a handful of drugs other than Daybue and Nuplazid for the treatment of other rare diseases as well, and each of these trials is showing strong promise. There are certainly worse, riskier investment prospects out there.
The only arguable downside to stepping into this stock right now is the sheer scope of today's gain, which has left behind a sizable gap from Thursday's high. Some investors may feel it needs to be backfilled first before shares can move higher.
Today's Change
(
9.44
%) $
2.24
Current Price
$
25.96
That pullback doesn't necessarily need to happen, to be clear. Some investors simply think it does.
Nevertheless, this worry can and likely will weigh on the stock for at least a few days. Interested risk-tolerant investors might want to wait for Friday's surge to settle down before stepping in.
This news comes during a mixed market day, with the health care sector gaining about 2.76%, while the broader S&P 500 remains flat.
• ACADIA Pharmaceuticals stock is charging ahead with explosive momentum. What’s fueling ACAD momentum?
ACAD Stock Jumps On CHMP Recommendation For DAYBU In EUThe CHMP has recommended granting marketing authorization for DAYBU (trofinetide), which, if approved by the European Commission, would be the first treatment for Rett syndrome symptoms in the EU.
This recommendation is based on positive results from the Phase 3 LAVENDER study, which showed significant improvements in core features of the condition.
In February, the CHMP voted negatively for trofinetide for Rett syndrome, following its recent CHMP oral explanation.
ACAD Technical Analysis: Momentum, Overbought Signals and ResistanceAcadia Pharmaceuticals is currently trading at $26.57, significantly above its 20-day simple moving average (SMA) of $22.02, indicating strong short-term momentum.
The stock is also 23.1% above its 20-day SMA, suggesting a bullish trend, although the relative strength index (RSI) is at 82.37, indicating that the stock is in overbought territory.
While the 50-day SMA is below the current price, the 50-day SMA has recently crossed below the 200-day SMA, marking a death cross in March, which could signal caution for longer-term investors.
The stock’s current price is also nearing key resistance at $28, which could be a pivotal point for future price action.
How ACAD Ranks On Value and MomentumBelow is the Benzinga Edge scorecard for Acadia Pharmaceuticals, highlighting its strengths and weaknesses compared to the broader market:
Value: 63.15 — The stock is reasonably valued relative to peers. Momentum: 29.67 — Stock is underperforming the broader market. The Verdict: Acadia Pharmaceuticals’ Benzinga Edge signal reveals a mixed profile, with a solid value ranking but weak momentum indicators. This suggests that while the stock may be fairly valued, it faces challenges in maintaining upward momentum in the current market environment.
Top ETFs Holding Acadia Pharmaceuticals (ACAD) Alger Weatherbie Enduring Growth ETF (NYSE:AWEG): 4.64% Weight ACAD Stock Price Activity: ACADIA Pharmaceuticals shares were up 8.60% at $26. at the time of publication on Friday, according to Benzinga Pro data.
Photo: Shutterstock
This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Market News and Data brought to you by Benzinga APIs
Founder's ClubSwingTraderLeaderboardMarketSurgeeIBDIBD DigitalIBD LiveCustomer Center
My Stock Lists
Email Preferences
Help & Support
Sign Out
Search stocks or keywords
Sections
My IBD
MARKET TREND
STOCK LISTS
STOCK RESEARCH
NEWSECONOMY
VIDEOS & PODCASTS
HOW TO INVESTEDUCATIONAL RESOURCESStoreMy Products
Founder's ClubSwingTraderLeaderboardMarketSurgeeIBDIBD DigitalIBD Live
Recently Searched
Flash Memory Chipmaker Sandisk Hits Record High, Leads 18 Onto Best Growth Stock Lists
OpenAI Mulls Delaying IPO Until 2027: Report
Nasdaq Extends Losing Streak Even As Micron Soars On Earnings; Apple Stock Dives Below Key Level Acadia stock popped Friday after European regulators unexpectedly reversed a previous decision, saying they would, in fact, recommend approval of the company's Rett syndrome drug, Daybu. Rett syndrome is a rare, neurological condition that affects primarily females. It causes progressive loss of purposeful hand use, language and motor coordination. Acadia Pharmaceuticals (ACAD) sells its drug under the brand Daybue in…
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by.
Shares of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the twenty brokerages that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, fourteen have assigned a buy
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced DAYBUE® STIX (trofinetide) for oral solution, a dye- and preservative-free powder formulation of trofinetide, is now broadly available in the United States for the treatment of Rett syndrome in adults and pediatric patients two years of age and older. The new formulation, approved by the U.S. Food and Drug Administration (FDA) in December 2025, is bioequivalent to the original DAYBUE® oral solution, delivering the same efficacy and safety profile, while offering children and adults living with Rett syndrome new flexibility and choice regarding the dose volume and taste of their DAYBUE treatment.1
"Initial feedback from a small group of caregivers following the limited launch revealed that more than 80% of early users reported satisfaction with DAYBUE STIX, highlighting the added flexibility and portability of this new formulation,"2 said Tom Garner, Acadia’s Chief Commercial Officer. “We are hearing that the new formulation may allow for more customized care in real-world settings. Ongoing evaluation from patients and caregivers remains a priority; their perspectives are essential as we identify ways to better assist families managing this complex condition.”
The importance of flexible, patient-centered approaches was reinforced in a recent publication of expert recommendations for real-world use of trofinetide in Rett syndrome. A steering group comprised of experts based at International Rett Syndrome Foundation (IRSF)-designated centers of excellence (COEs) reached consensus recognizing trofinetide oral solution as part of the standard of care for individuals with Rett syndrome. They also aligned on key real-world considerations such as early initiation and sustained use over time. The recommendations also reflect shared perspectives on the need for individualized decision making in clinical practice to help optimize outcomes for patients, families, and caregivers.3
“The availability of DAYBUE STIX gives us an additional, flexible way to administer trofinetide, which allows us more options to address unique patient and caregiver needs,” said Arthur Beisang, M.D., Department of Pediatrics, Gillette Children's Specialty Healthcare, Saint Paul, Minn. “This patient-centered approach aligns with recently published expert consensus recommendations, which advocate for the integration of trofinetide as part of the standard of care and comprehensive Rett syndrome management. This new option provides additional customization, supporting individualized care for people with Rett syndrome.”
DAYBUE STIX is a for oral solution powder that caregivers can mix with a variety of water-based liquids such as juice, tea, lemonade, limeade, or liquid hydration so that caregivers have the ability to customize to their loved ones' taste.4 The product comes in individual packets that are easily portable.
The efficacy and safety of DAYBUE STIX is based on the results of the pivotal Phase 3 LAVENDER™ study with DAYBUE oral solution in patients with Rett syndrome.4 The approval of this new formulation was informed by the results of a bioequivalence study, which demonstrated that both original DAYBUE oral solution and the new DAYBUE STIX for oral solution powder formulation provide comparable exposure.1
Families interested in exploring this new option should speak with their healthcare provider. Acadia also offers families access to Acadia Connect®, a multi-faceted support program that offers a dedicated, experienced support team assisting with financial resources and prescription support to patients and caregivers throughout the DAYBUE treatment journey. The original oral solution formulation approved by the U.S. Food and Drug Administration in 2023 will remain available.
About Rett Syndrome
Rett syndrome is a rare, complex, neurodevelopmental disorder that may occur over four stages and occurs in approximately one of every 10,000 to 15,000 female births worldwide.5-7 In the U.S., 6,000 to 9,000 patients are affected.8 A child with Rett syndrome exhibits an early period of apparently normal development until six to 18 months, when their skills seem to slow down or stagnate. This is typically followed by a duration of regression when the child loses acquired communication skills and purposeful hand use. The child may then experience a plateau period in which they show mild recovery in cognitive interests, but body movements remain severely diminished. As they age, those living with Rett may continue to experience a stage of motor deterioration, which can last the rest of the patient’s life.6 Rett syndrome is typically caused by a genetic mutation on the MECP2 gene.9 In preclinical studies, deficiency in MeCP2 function is thought to lead to impairment in synaptic communication, and the deficits in synaptic function may be associated with Rett manifestations.9-11
Symptoms of Rett syndrome may also include development of hand stereotypies, such as hand wringing and clapping, and gait abnormalities.12 Most Rett patients typically live into adulthood and require round-the-clock care.5,13
About DAYBUE® (trofinetide) and DAYBUE® STIX (trofinetide)
Trofinetide is a synthetic analog of the N-terminal tripeptide of insulin-like growth factor-1. The mechanism by which trofinetide exerts therapeutic effects in patients with Rett syndrome is unknown. In animal studies, trofinetide has been shown to increase branching of dendrites and synaptic plasticity signals.14
Indication and Important Safety Information for DAYBUE® (trofinetide) and DAYBUE® STIX (trofinetide)
Indication
DAYBUE and DAYBUE STIX are indicated for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older.
Important Safety Information
Warnings and Precautions Diarrhea: In a 12-week study and in long-term studies, 85% of patients treated with DAYBUE experienced diarrhea. In those treated with DAYBUE, 49% either had persistent diarrhea or recurrence after resolution despite dose interruptions, reductions, or concomitant antidiarrheal therapy. Diarrhea severity was mild or moderate in 96% of cases. In the 12-week study, antidiarrheal medication was used in 51% of patients treated with DAYBUE.
Advise patients to stop laxatives before starting DAYBUE or DAYBUE STIX. If diarrhea occurs, patients should notify their healthcare provider, consider starting antidiarrheal treatment, and monitor hydration status and increase oral fluids, if needed. Interrupt, reduce dose, or discontinue DAYBUE or DAYBUE STIX if severe diarrhea occurs or if dehydration is suspected. Vomiting: In a 12-week study, vomiting occurred in 29% of patients treated with DAYBUE and in 12% of patients who received placebo.
Patients with Rett syndrome are at risk for aspiration and aspiration pneumonia. Aspiration and aspiration pneumonia have been reported following vomiting in patients being treated with DAYBUE. Interrupt, reduce dose, or discontinue DAYBUE or DAYBUE STIX if vomiting is severe or occurs despite medical management. Weight Loss: In the 12-week study, 12% of patients treated with DAYBUE experienced weight loss of greater than 7% from baseline, compared to 4% of patients who received placebo. In long-term studies, 2.2% of patients discontinued treatment with DAYBUE due to weight loss. Monitor weight and interrupt, reduce dose, or discontinue DAYBUE or DAYBUE STIX if significant weight loss occurs. Adverse Reactions: The common adverse reactions (≥5% for DAYBUE-treated patients and at least 2% greater than in placebo) reported in the 12-week study were diarrhea (82% vs 20%), vomiting (29% vs 12%), fever (9% vs 4%), seizure (9% vs 6%), anxiety (8% vs 1%), decreased appetite (8% vs 2%), fatigue (8% vs 2%), and nasopharyngitis (5% vs 1%). Drug Interactions: Effect of DAYBUE and DAYBUE STIX on other Drugs Trofinetide, a weak inhibitor of CYP3A and an inhibitor of P-gp, can increase the plasma concentrations of CYP3A and/or P-gp substrates (e.g., loperamide), which may increase the risk of adverse reactions associated with these substrates.
Closely monitor patients when DAYBUE or DAYBUE STIX is administered concomitantly with sensitive CYP3A and/or P-gp substrates for which a minimal increase in substrate plasma concentration (i.e., drugs with a narrow therapeutic index) may lead to serious adverse reactions. Use in Specific Population: Renal Impairment DAYBUE and DAYBUE STIX are not recommended for patients with severe renal impairment. DAYBUE is available as an oral solution (200 mg/mL).
DAYBUE STIX for oral solution powder is available in 5,000 mg, 6,000 mg, and 8,000 mg packets.
Please read the full Prescribing Information also available at DAYBUEhcp.com.
About Acadia Pharmaceuticals
Acadia is committed to turning scientific promise into meaningful innovation that makes the difference for underserved neurological and rare disease communities around the world. Our commercial portfolio includes the first and only FDA-approved treatments for Parkinson’s disease psychosis and Rett syndrome. We are developing the next wave of therapeutic advancements with a robust and diverse pipeline that includes mid- to late-stage programs in Alzheimer’s disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. At Acadia, we’re here to be their difference. For more information, visit us at acadia.com and follow us on LinkedIn and X.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements other than statements of historical fact and can be identified by terms such as “may,” “will,” “should,” “expects,” “anticipates,” and similar expressions (including the negative thereof) intended to identify forward-looking statements. Forward-looking statements contained in this press release, include, but are not limited to, statements about: (i) the efficacy and safety profile of DAYBUE and DAYBUE STIX and anticipated Rett syndrome symptom improvements, (ii) the flexibility in administration and allowance for customized care provided by DAYBUE STIX, (iii) the use of DAYBUE and DAYBUE STIX as the standard of care for patients with Rett syndrome and (iv) potential future use of DAYBUE and DAYBUE STIX. Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. Such risks, uncertainties, assumptions and other factors include, but are not limited to: our ability to continue to successfully commercialize DAYBUE and DAYBUE STIX and our ability to continue to stay in compliance with applicable laws and regulations. Given the risks and uncertainties, you should not place undue reliance on these forward-looking statements. For a discussion of these and other risks, uncertainties, assumptions and other factors that may cause our actual results, performance or achievements to differ, please refer to our annual report on Form 10-K for the year ended December 31, 2025 filed with the Securities and Exchange Commission on February 26, 2026, as well as our subsequent filings with the Securities and Exchange Commission from time to time. The forward-looking statements contained herein are made as of the date hereof, and we undertake no obligation to update them after this date, except as required by law.
References
1
Mona D, Yamamoto A, Adegbenle Y, et al. A Phase 1, Randomized, Open-Label Study to Assess the Bioequivalence of Trofinetide as a Ready-to-Use Oral Solution and Constituted Powder for Oral Solution in Healthy Adults. Adv Ther. 2026.
2
Acadia Pharmaceuticals Inc., Data on file.
3
Prange EO, Beisang A, Pehlivan D, et al. Expert Consensus on Real-World Use of Trofinetide for Rett Syndrome Using a Modified Delphi Method. Ann Child Neurol. 2026; 4:38-51
4
Acadia Pharmaceuticals Inc. DAYBUE® [package insert]. San Diego, CA; 2025
5
Fu C, Armstrong D, Marsh E, et al. Consensus guidelines on managing Rett syndrome across the lifespan. BMJ Paediatrics Open. 2020; 4:1-14.
6
Kyle SM, Vashi N, Justice MJ. Rett syndrome: a neurological disorder with metabolic components. Open Biol. 2018; 8:170216.
7
May DM, Neul JL, Satija A, et al. Real-world clinical management of individuals with Rett syndrome: a physician survey. J of Med Econ. 26(1), 1570–1580.
8
Acadia Pharmaceuticals Inc., Data on file. RTT US Prevalence. March 2022.
9
Amir RE, Van den Veyver IB, Wan M, et al. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet. 1999; 23(2):185-188.
10
Fukuda T, Itoh M, Ichikawa T, et al. Delayed maturation of neuronal architecture and synaptogenesis in cerebral cortex of Mecp2-deficient mice. J Neuropathol Exp Neurol. 2005; 64(6):537-544.
11
Asaka Y, Jugloff DG, Zhang L, et al. Hippocampal synaptic plasticity is impaired in the Mecp2-null mouse model of Rett syndrome. Neurobiol Dis. 2006; 21(1):217-227.
12
Neul JL, Kaufmann WE, Glaze DG, et al. Rett syndrome: revised diagnostic criteria and nomenclature. Ann Neurol. 2010; 68(6):944-950.
13
Tarquinio DO, Hou W, Neul JL, et al. The changing face of survival in Rett syndrome and MECP2-related disorders. Pediatr Neurol. 2015; 53(5):402-411.
14
Acadia Pharmaceuticals Inc., Data on file. Study Report 2566-026. 2010.
Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Acadia Pharmaceuticals (ACAD - Free Report) , which belongs to the Zacks Medical - Biomedical and Genetics industry.
This drugmaker has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the last two quarters was 59.52%.
For the last reported quarter, Acadia came out with earnings of $0.16 per share versus the Zacks Consensus Estimate of $0.12 per share, representing a surprise of 33.33%. For the previous quarter, the company was expected to post earnings of $0.14 per share and it actually produced earnings of $0.26 per share, delivering a surprise of 85.71%.
Price and EPS Surprise
For Acadia, estimates have been trending higher, thanks in part to this earnings surprise history. And when you look at the stock's positive Zacks Earnings ESP (Expected Surprise Prediction), it's a great indicator of a future earnings beat, especially when combined with its solid Zacks Rank.
Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank #3 (Hold) or better produce a positive surprise nearly 70% of the time. In other words, if you have 10 stocks with this combination, the number of stocks that beat the consensus estimate could be as high as seven.
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Acadia has an Earnings ESP of +113.33% at the moment, suggesting that analysts have grown bullish on its near-term earnings potential. When you combine this positive Earnings ESP with the stock's Zacks Rank #3 (Hold), it shows that another beat is possibly around the corner.
Investors should note, however, that a negative Earnings ESP reading is not indicative of an earnings miss, but a negative value does reduce the predictive power of this metric.
Many companies end up beating the consensus EPS estimate, though this is not the only reason why their shares gain. Additionally, some stocks may remain stable even if they end up missing the consensus estimate.
Because of this, it's really important to check a company's Earnings ESP ahead of its quarterly release to increase the odds of success. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report) EVP Mark Schneyer sold 2,709 shares of the firm’s stock in a transaction on Tuesday, April 7th. The shares were sold at an average price of $22.20, for a total value of $60,139.80. Following the transaction, the executive vice president directly owned 62,836 shares in the company, valued at $1,394,959.20. This trade represents a 4.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link.
ACADIA Pharmaceuticals Stock Performance Shares of ACAD opened at $22.56 on Thursday. The firm has a market capitalization of $3.85 billion, a price-to-earnings ratio of 9.85, a price-to-earnings-growth ratio of 22.07 and a beta of 0.83. ACADIA Pharmaceuticals Inc. has a one year low of $13.40 and a one year high of $28.35. The stock’s fifty day moving average is $22.69 and its 200-day moving average is $23.79.
ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) last released its earnings results on Thursday, February 26th. The biopharmaceutical company reported $1.60 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.12 by $1.48. The firm had revenue of $298.00 million for the quarter, compared to analyst estimates of $292.54 million. ACADIA Pharmaceuticals had a return on equity of 12.49% and a net margin of 36.49%.ACADIA Pharmaceuticals’s revenue was up 9.4% compared to the same quarter last year. During the same period in the previous year, the company earned $0.86 earnings per share. Analysts forecast that ACADIA Pharmaceuticals Inc. will post 0.7 EPS for the current fiscal year.
More ACADIA Pharmaceuticals News Here are the key news stories impacting ACADIA Pharmaceuticals this week:
Positive Sentiment: Analysts/Zacks note ACAD’s history of quarterly earnings surprises and say the company currently has the key attributes that make another beat likely — supporting upside into the next report. Will Acadia (ACAD) Beat Estimates Again in Its Next Earnings Report? (Yahoo) Will Acadia (ACAD) Beat Estimates Again in Its Next Earnings Report? (Zacks) Positive Sentiment: Acadia launched DAYBUE® STIX (trofinetide) — a dye- and preservative-free powder formulation of its Rett syndrome medicine — and said it is now broadly available in the U.S.; FDA-approved bioequivalence and easier dosing could boost uptake and sales. Acadia Announces DAYBUE STIX Now Broadly Available (BusinessWire) Positive Sentiment: Analyst coverage and institutional activity are constructive: several firms raised price targets or hold “outperform/overweight” views, and reports show large institutional stakes increasing — a supportive backdrop for the shares. Acadia Pharmaceuticals: A Mid-Cap Biotech Making Large Moves (MarketBeat) Neutral Sentiment: Recent fundamentals: ACAD posted a sizable EPS beat in its last quarter (reported $1.60 vs. $0.12 est.) and revenue growth (~9% y/y); valuation metrics (low-teens P/E) and its 50/200-day moving averages are mixed signals for different investor horizons. ACAD Price & Profile (MarketBeat) Negative Sentiment: Insider selling: EVP Mark C. Schneyer sold 2,709 shares and director/executive James Kihara sold 1,030 shares at about $22.20 on April 7; while dollar amounts are modest relative to institutional holdings, insider sales can raise short-term caution for some investors. James Kihara Sells 1,030 Shares of ACADIA Pharmaceuticals (InsiderTrades) SEC Form 4 (Kihara) SEC Form 4 (Schneyer) Hedge Funds Weigh In On ACADIA Pharmaceuticals Hedge funds and other institutional investors have recently modified their holdings of the stock. Farther Finance Advisors LLC boosted its position in shares of ACADIA Pharmaceuticals by 67.5% in the 4th quarter. Farther Finance Advisors LLC now owns 958 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 386 shares during the period. Meeder Asset Management Inc. acquired a new position in shares of ACADIA Pharmaceuticals in the 4th quarter valued at $26,000. Geneos Wealth Management Inc. boosted its position in shares of ACADIA Pharmaceuticals by 113.0% in the 3rd quarter. Geneos Wealth Management Inc. now owns 1,425 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 756 shares during the period. Smartleaf Asset Management LLC boosted its position in shares of ACADIA Pharmaceuticals by 107.0% in the 3rd quarter. Smartleaf Asset Management LLC now owns 1,712 shares of the biopharmaceutical company’s stock valued at $36,000 after purchasing an additional 885 shares during the period. Finally, Transamerica Financial Advisors LLC boosted its position in shares of ACADIA Pharmaceuticals by 304.5% in the 4th quarter. Transamerica Financial Advisors LLC now owns 1,335 shares of the biopharmaceutical company’s stock valued at $36,000 after purchasing an additional 1,005 shares during the period. Institutional investors and hedge funds own 96.71% of the company’s stock.
Analyst Ratings Changes A number of research firms recently issued reports on ACAD. JPMorgan Chase & Co. lifted their target price on ACADIA Pharmaceuticals from $31.00 to $34.00 and gave the stock an “overweight” rating in a report on Wednesday, March 4th. Citizens Jmp lifted their target price on ACADIA Pharmaceuticals from $34.00 to $35.00 and gave the stock a “market outperform” rating in a report on Thursday, February 26th. Piper Sandler set a $37.00 target price on ACADIA Pharmaceuticals in a report on Tuesday, December 16th. Oppenheimer reaffirmed a “market perform” rating on shares of ACADIA Pharmaceuticals in a report on Friday, February 6th. Finally, Wolfe Research began coverage on ACADIA Pharmaceuticals in a report on Monday, February 23rd. They set an “outperform” rating and a $33.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, ACADIA Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $31.21.
Check Out Our Latest Research Report on ACAD
About ACADIA Pharmaceuticals (Get Free Report)
ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.
The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.
Featured Stories Five stocks we like better than ACADIA Pharmaceuticals
Receive News & Ratings for ACADIA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both CSL Limited Sponsored ADR (CSLLY - Free Report) and Acadia Pharmaceuticals (ACAD - Free Report) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.
Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Style Scores highlight companies with specific traits.
CSL Limited Sponsored ADR has a Zacks Rank of #2 (Buy), while Acadia Pharmaceuticals has a Zacks Rank of #3 (Hold) right now. The Zacks Rank favors stocks that have recently seen positive revisions to their earnings estimates, so investors should rest assured that CSLLY has an improving earnings outlook. But this is only part of the picture for value investors.
Value investors analyze a variety of traditional, tried-and-true metrics to help find companies that they believe are undervalued at their current share price levels.
The Style Score Value grade factors in a variety of key fundamental metrics, including the popular P/E ratio, P/S ratio, earnings yield, cash flow per share, and a number of other key stats that are commonly used by value investors.
CSLLY currently has a forward P/E ratio of 14.14, while ACAD has a forward P/E of 45.75. We also note that CSLLY has a PEG ratio of 1.60. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. ACAD currently has a PEG ratio of 21.38.
Another notable valuation metric for CSLLY is its P/B ratio of 2.23. The P/B is a method of comparing a stock's market value to its book value, which is defined as total assets minus total liabilities. By comparison, ACAD has a P/B of 2.96.
Based on these metrics and many more, CSLLY holds a Value grade of B, while ACAD has a Value grade of C.
CSLLY sticks out from ACAD in both our Zacks Rank and Style Scores models, so value investors will likely feel that CSLLY is the better option right now.
Company to host conference call and webcast on Wednesday, May 6, 2026, at 4:30 p.m. Eastern Time
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report first quarter 2026 financial results on Wednesday, May 6, 2026, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on May 6, 2026, at 4:30 p.m. Eastern Time.
The conference call will be available on Acadia’s website, acadia.com under the investors section and will be archived there until August 15, 2026. The conference call may also be accessed by registering for the call here. Once registered, participants will receive an email with the dial-in number and unique PIN number to use for accessing the call.
About Acadia Pharmaceuticals
Acadia is committed to turning scientific promise into meaningful innovation that makes the difference for underserved neurological and rare disease communities around the world. Our commercial portfolio includes the first and only FDA-approved treatments for Parkinson’s disease psychosis and Rett syndrome. We are developing the next wave of therapeutic advancements with a robust and diverse pipeline that includes mid- to late-stage programs in Alzheimer’s disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. At Acadia, we’re here to be their difference. For more information, visit us at acadia.com and follow us on LinkedIn and X.
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present multiple original data presentations spanning its portfolio at the 2026 American Academy of Neurology (AAN) Annual Meeting, taking place April 18–22, 2026 in Chicago, IL.
The Company will present real-world data from a sub-group analysis of the ongoing, Phase 4, prospective, observational, open-label LOTUS study evaluating the benefits and tolerability of DAYBUE® (trofinetide) in adults with Rett syndrome in routine clinical practice. In support of NUPLAZID® (pimavanserin) in Parkinson’s disease psychosis (PDP), Acadia will present exploratory analyses evaluating heterogeneity in treatment response trajectories and the impact of baseline sleep disturbances among PDP patients treated with pimavanserin. The Company is also debuting translational and pharmacokinetic research supporting the continued development of ACP-711, an investigational drug, for essential tremor. Collectively, these data reflect Acadia’s ongoing commitment to advancing scientific knowledge across a wide range of neurological conditions.
AAN Poster Presentations
P11.005: Real-world Benefits and Tolerability of Trofinetide for the Treatment of Adults with Rett Syndrome: the LOTUS Study, Wednesday, April 22, 11:45 AM – 12:45 PM CT P11.006: Response Trajectories of Patients with Parkinson’s Disease Psychosis Treated with Pimavanserin: An Exploratory Cluster Analysis, Wednesday, April 22, 11:45 AM – 12:45 PM CT P11.007: Impact of Baseline Sleep Disturbances on Pimavanserin Response in Parkinson’s Disease Psychosis: A Post Hoc Analysis, Wednesday, April 22, 11:45 AM – 12:45 PM CT P7.007: Development of ACP-711, a Selective Modulator of GABA-A Receptor a3, for Essential Tremor: Use of First-in-Human Phase 1 Pharmacokinetics and Pharmacodynamics to Identify Target Dose/Exposure, Tuesday, April 21, 8:00 AM – 9:00 AM CT P8.012: Mechanism of Action, Preclinical Efficacy, and Safety Evaluation of ACP-711 (SAN711): A Novel GABAA Subunit a3 Selective Modulator, Tuesday, April 21, 11:45 AM – 12:45 PM CT About DAYBUE® (trofinetide) and DAYBUE® STIX (trofinetide)
Trofinetide is a synthetic analog of the N-terminal tripeptide of insulin-like growth factor-1. The mechanism by which trofinetide exerts therapeutic effects in patients with Rett syndrome is unknown. In animal studies, trofinetide has been shown to increase branching of dendrites and synaptic plasticity signals.1
Indication and Important Safety Information for DAYBUE® (trofinetide) and DAYBUE® STIX (trofinetide)
Indication
DAYBUE and DAYBUE STIX are indicated for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older.
Important Safety Information
Warnings and Precautions Diarrhea: In a 12-week study and in long-term studies, 85% of patients treated with DAYBUE experienced diarrhea. In those treated with DAYBUE, 49% either had persistent diarrhea or recurrence after resolution despite dose interruptions, reductions, or concomitant antidiarrheal therapy. Diarrhea severity was mild or moderate in 96% of cases. In the 12-week study, antidiarrheal medication was used in 51% of patients treated with DAYBUE.
Advise patients to stop laxatives before starting DAYBUE or DAYBUE STIX. If diarrhea occurs, patients should notify their healthcare provider, consider starting antidiarrheal treatment, and monitor hydration status and increase oral fluids, if needed. Interrupt, reduce dose, or discontinue DAYBUE or DAYBUE STIX if severe diarrhea occurs or if dehydration is suspected. Vomiting: In a 12-week study, vomiting occurred in 29% of patients treated with DAYBUE and in 12% of patients who received placebo.
Patients with Rett syndrome are at risk for aspiration and aspiration pneumonia. Aspiration and aspiration pneumonia have been reported following vomiting in patients being treated with DAYBUE. Interrupt, reduce dose, or discontinue DAYBUE or DAYBUE STIX if vomiting is severe or occurs despite medical management. Weight Loss: In the 12-week study, 12% of patients treated with DAYBUE experienced weight loss of greater than 7% from baseline, compared to 4% of patients who received placebo. In long-term studies, 2.2% of patients discontinued treatment with DAYBUE due to weight loss. Monitor weight and interrupt, reduce dose, or discontinue DAYBUE or DAYBUE STIX if significant weight loss occurs. Adverse Reactions: The common adverse reactions (≥5% for DAYBUE-treated patients and at least 2% greater than in placebo) reported in the 12-week study were diarrhea (82% vs 20%), vomiting (29% vs 12%), fever (9% vs 4%), seizure (9% vs 6%), anxiety (8% vs 1%), decreased appetite (8% vs 2%), fatigue (8% vs 2%), and nasopharyngitis (5% vs 1%). Drug Interactions: Effect of DAYBUE and DAYBUE STIX on other Drugs Trofinetide, a weak inhibitor of CYP3A and an inhibitor of P-gp, can increase the plasma concentrations of CYP3A and/or P-gp substrates (e.g., loperamide), which may increase the risk of adverse reactions associated with these substrates .
Closely monitor patients when DAYBUE or DAYBUE STIX is administered concomitantly with sensitive CYP3A and/or P-gp substrates for which a minimal increase in substrate plasma concentration (i.e., drugs with a narrow therapeutic index) may lead to serious adverse reactions. Use in Specific Population: Renal Impairment DAYBUE and DAYBUE STIX are not recommended for patients with severe renal impairment. DAYBUE is available as an oral solution (200 mg/mL).
DAYBUE STIX for oral solution powder is available in 5,000 mg, 6,000 mg, and 8,000 mg packets.
Please read the full Prescribing Information also available at DAYBUEhcp.com.
About NUPLAZID® (pimavanserin)
Pimavanserin is a selective serotonin inverse agonist and antagonist preferentially targeting 5-HT2A receptors. These receptors are thought to play an important role in neuropsychiatric disorders. In vitro, pimavanserin demonstrated no appreciable binding affinity for dopamine (including D2), histamine, muscarinic, or adrenergic receptors. Pimavanserin was approved for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis by the U.S. Food and Drug Administration in April 2016 under the trade name NUPLAZID.
Indication
NUPLAZID is indicated for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.
Important Safety Information
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. NUPLAZID is not approved for the treatment of patients with dementia who experience psychosis unless their hallucinations and delusions are related to Parkinson’s disease. Contraindication: NUPLAZID is contraindicated in patients with a history of a hypersensitivity reaction to pimavanserin or any of its components. Rash, urticaria, and reactions consistent with angioedema (e.g., tongue swelling, circumoral edema, throat tightness, and dyspnea) have been reported. Warnings and Precautions: QT Interval Prolongation NUPLAZID prolongs the QT interval. The use of NUPLAZID should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong QT interval (e.g., Class 1A antiarrhythmics, Class 3 antiarrhythmics, certain antipsychotics or antibiotics). NUPLAZID should also be avoided in patients with a history of cardiac arrhythmias, as well as other circumstances that may increase the risk of the occurrence of torsade de pointes and/or sudden death, including symptomatic bradycardia, hypokalemia or hypomagnesemia, and presence of congenital prolongation of the QT interval. Adverse Reactions: The adverse reactions (≥2% for NUPLAZID and greater than placebo) were peripheral edema (7% vs 2%), nausea (7% vs 4%), confusional state (6% vs 3%), hallucination (5% vs 3%), constipation (4% vs 3%), and gait disturbance (2% vs <1%). Drug Interactions: Coadministration with strong CYP3A4 inhibitors increases NUPLAZID exposure. Reduce NUPLAZID dose to 10 mg taken orally as one tablet once daily. Coadministration with strong or moderate CYP3A4 inducers reduces NUPLAZID exposure. Avoid concomitant use of strong or moderate CYP3A4 inducers with NUPLAZID. Dosage and Administration
Recommended dose: 34 mg capsule taken orally once daily, without titration, with or without food.
NUPLAZID is available as 34 mg capsules and 10 mg tablets.
Please read the full Prescribing Information, including Boxed WARNING, also available at NUPLAZIDhcp.com.
About Acadia Pharmaceuticals
Acadia is committed to turning scientific promise into meaningful innovation that makes the difference for underserved neurological and rare disease communities around the world. Our commercial portfolio includes the first and only FDA-approved treatments for Parkinson’s disease psychosis and Rett syndrome. We are developing the next wave of therapeutic advancements with a robust and diverse pipeline that includes mid- to late-stage programs in Alzheimer’s disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. At Acadia, we’re here to be their difference. For more information, visit us at acadia.com and follow us on LinkedIn and X.
References
Acadia Pharmaceuticals Inc., Data on file. Study Report 2566-026. 2010. More News From Acadia Pharmaceuticals Inc.
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at two upcoming investor conferences:
BofA Securities 2026 Health Care Conference
Fireside Chat: Tuesday, May 12, 2026 at 4:20 p.m. Pacific Time in Las Vegas, NV
2026 RBC Capital Markets Global Healthcare Conference
Fireside Chat: Tuesday, May 19, 2026 at 9:00 a.m. Eastern Time in New York, NY
Live webcasts will be accessible on the company’s website, acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following each presentation.
About Acadia Pharmaceuticals
Acadia is committed to turning scientific promise into meaningful innovation that makes the difference for underserved neurological and rare disease communities around the world. Our commercial portfolio includes the first and only FDA-approved treatments for Parkinson’s disease psychosis and Rett syndrome. We are developing the next wave of therapeutic advancements with a robust and diverse pipeline that includes mid- to late-stage programs in Alzheimer’s disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. At Acadia, we’re here to be their difference. For more information, visit us at acadia.com and follow us on LinkedIn and X.
Acadia Pharmaceuticals (ACAD - Free Report) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended March 2026. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.
The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on May 6. On the other hand, if they miss, the stock may move lower.
While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.
Zacks Consensus EstimateThis drugmaker is expected to post quarterly earnings of $0.04 per share in its upcoming report, which represents a year-over-year change of -63.6%.
Revenues are expected to be $281.75 million, up 15.3% from the year-ago quarter.
Estimate Revisions TrendThe consensus EPS estimate for the quarter has been revised 7.89% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.
Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.
Price, Consensus and EPS Surprise
Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction).
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.
A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.
Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).
How Have the Numbers Shaped Up for Acadia?For Acadia, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have recently become bullish on the company's earnings prospects. This has resulted in an Earnings ESP of +100.00%.
On the other hand, the stock currently carries a Zacks Rank of #3.
So, this combination indicates that Acadia will most likely beat the consensus EPS estimate.
Does Earnings Surprise History Hold Any Clue?Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.
For the last reported quarter, it was expected that Acadia would post earnings of $0.12 per share when it actually produced earnings of $0.16, delivering a surprise of +33.33%.
Over the last four quarters, the company has beaten consensus EPS estimates four times.
Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.
That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
Acadia appears a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.
Expected Results of an Industry PlayerAnother stock from the Zacks Medical - Biomedical and Genetics industry, Fortrea Holdings Inc. (FTRE - Free Report) , is soon expected to post earnings of $0.03 per share for the quarter ended March 2026. This estimate indicates a year-over-year change of +50%. Revenues for the quarter are expected to be $636.94 million, down 2.2% from the year-ago quarter.
The consensus EPS estimate for Fortrea Holdings Inc. has been revised 1% lower over the last 30 days to the current level. However, a lower Most Accurate Estimate has resulted in an Earnings ESP of -65.12%.
This Earnings ESP, combined with its Zacks Rank #3 (Hold), makes it difficult to conclusively predict that Fortrea Holdings Inc. will beat the consensus EPS estimate. Over the last four quarters, the company surpassed consensus EPS estimates two times.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with CSL Limited Sponsored ADR (CSLLY - Free Report) and Acadia Pharmaceuticals (ACAD - Free Report) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.
The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The Zacks Rank is a proven strategy that targets companies with positive earnings estimate revision trends, while our Style Scores work to grade companies based on specific traits.
Right now, CSL Limited Sponsored ADR is sporting a Zacks Rank of #2 (Buy), while Acadia Pharmaceuticals has a Zacks Rank of #3 (Hold). This means that CSLLY's earnings estimate revision activity has been more impressive, so investors should feel comfortable with its improving analyst outlook. But this is only part of the picture for value investors.
Value investors also tend to look at a number of traditional, tried-and-true figures to help them find stocks that they believe are undervalued at their current share price levels.
The Value category of the Style Scores system identifies undervalued companies by looking at a number of key metrics. These include the long-favored P/E ratio, P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that help us determine a company's fair value.
CSLLY currently has a forward P/E ratio of 12.78, while ACAD has a forward P/E of 49.66. We also note that CSLLY has a PEG ratio of 1.45. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. ACAD currently has a PEG ratio of 23.21.
Another notable valuation metric for CSLLY is its P/B ratio of 2.11. The P/B ratio pits a stock's market value against its book value, which is defined as total assets minus total liabilities. For comparison, ACAD has a P/B of 3.06.
Based on these metrics and many more, CSLLY holds a Value grade of B, while ACAD has a Value grade of C.
CSLLY has seen stronger estimate revision activity and sports more attractive valuation metrics than ACAD, so it seems like value investors will conclude that CSLLY is the superior option right now.
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the planned retirement of Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development. Dr. Thompson has decided to retire for personal reasons and informed Acadia of her plans. She will continue in her role as Head of Research and Development until a successor is appointed. After her retirement, Acadia plans to retain Dr. Thompson as a consultant through at least the end of 2026 to ensure scientific and leadership continuity through the planned readout of the Phase 2 clinical study of remlifanserin in Alzheimer’s disease psychosis (ADP) and into early Phase 3 clinical study execution.
Acadia has initiated a search for a new Head of Research and Development and is committed to identifying an experienced R&D leader who will build on the strong scientific foundation already in place. The Company continues to advance its clinical development programs as planned. All ongoing clinical trials, including the Phase 2 studies of remlifanserin in ADP and Lewy Body Dementia Psychosis (LBDP), continue to recruit and remain blinded, and the Company, including Dr. Thompson, does not yet know study outcomes.
“Liz’s leadership has been instrumental in strengthening Acadia’s research and development organization, both scientifically and operationally, and in advancing a clear, disciplined R&D strategy across our pipeline,” said Catherine Owen Adams, Chief Executive Officer of Acadia. “She has been a strong advocate for the patients we serve and at every step has ensured thoughtful execution and prioritization of our programs in neurological and rare diseases. Just as importantly, Liz fostered a culture of clarity, accountability, and engagement across R&D. We are grateful for her continued commitment to Acadia during the transition period and for her willingness to remain engaged as a consultant, providing continuity of scientific leadership and institutional perspective in support of our mission and, most importantly, the patients we serve.”
“Leading Acadia’s research and development organization has been a defining chapter in my career and one in which I take a great deal of pride,” said Dr. Thompson. “We started from a great foundation, and have been able to build and strengthen the Acadia R&D team as well as make good progress in shaping and advancing a curated pipeline. I am particularly pleased with how we’ve been able to strengthen the remlifanserin program, especially by expanding it into Lewy Body Dementia Psychosis. I remain excited by the potential for remlifanserin and confident in the disciplined development strategy the Acadia team is executing. Beyond remlifanserin, our pipeline contains multiple programs that could represent truly meaningful options for patients living with neurological and rare diseases. While I have decided to retire for personal reasons, I am committed to continuing to lead the organization until the appointment of a successor and to supporting Acadia through the transition and the remainder of the year.”
Dr. Thompson joined Acadia in 2024 serving as Head of Research and Development. During her tenure, she helped strengthen the Company’s scientific and clinical capabilities, advance multiple development programs, and foster a culture of collaboration across research, clinical development and regulatory teams.
About Acadia Pharmaceuticals
Acadia is committed to turning scientific promise into meaningful innovation that makes the difference for underserved neurological and rare disease communities around the world. Our commercial portfolio includes the first and only FDA-approved treatments for Parkinson’s disease psychosis and Rett syndrome. We are developing the next wave of therapeutic advancements with a robust and diverse pipeline that includes mid- to late-stage programs in Alzheimer’s disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. At Acadia, we’re here to be their difference. For more information, visit us at acadia.com and follow us on LinkedIn and X.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements other than statements of historical fact and can be identified by terms such as “may,” “will,” “should,” “expects,” “anticipates,” “continues,” “intends,” “planned,” and similar expressions (including the negative thereof) intended to identify forward-looking statements. Forward-looking statements contained in this press release, include, but are not limited to, statements about: (i) Dr. Thompson’s planned retirement, and her continued service in her role through a transitional period and as a consultant with the Company, (ii) our ability to recruit and timely hire a new Head of Research and Development, and (iii) the advancement of the Company’s clinical development programs, including the timely achievement of anticipated clinical milestones. Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. Such risks, uncertainties, assumptions and other factors include, but are not limited to Dr. Thompson’s continued services to the Company, future executive recruitment and the advancement of clinical development programs. Given the risks and uncertainties, you should not place undue reliance on these forward-looking statements. For a discussion of these and other risks, uncertainties, assumptions and other factors that may cause our actual results, performance or achievements to differ, please refer to our annual report on Form 10-K for the year ended December 31, 2025 filed with the Securities and Exchange Commission on February 26, 2026, as well as our subsequent filings with the Securities and Exchange Commission from time to time. The forward-looking statements contained herein are made as of the date hereof, and we undertake no obligation to update them after this date, except as required by law.
- First quarter DAYBUE® GAAP net sales of $101 million, up 20% year-over-year; successful launch of DAYBUE STIX underway
- First quarter NUPLAZID® GAAP net sales of $167 million, up 6% year-over-year on a non-GAAP adjusted basis
- Reaffirms expectation for topline results from the Phase 2 remlifanserin study in Alzheimer’s disease psychosis between August and October 2026
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the first quarter ended March 31, 2026.
“Acadia delivered a solid first quarter of 2026 with total revenues of $268 million, driven by a strong start from DAYBUE, which generated sales of $101 million,” said Catherine Owen Adams, Chief Executive Officer. “We are very encouraged by the early enthusiasm for DAYBUE STIX, which is now broadly available in the U.S., and by the initial uptake during our focused launch. NUPLAZID generated sales of $167 million, supported by strong new referrals and underlying demand, with performance strengthening as the quarter progressed. As we look ahead, we remain focused on advancing our deep, differentiated pipeline, with remlifanserin representing a key value driver as we approach expected Phase 2 topline data in Alzheimer’s disease psychosis later this year. We are reaffirming our full year guidance and remain confident in our ability to deliver long‑term value for both patients and shareholders.”
Company Updates
Full launch of DAYBUE STIX (trofinetide) in the U.S. is underway, with ~30% of STIX patients being either treatment-naive or returning after previously discontinuing the liquid formulation. Phase 2 topline results readout from the remlifanserin Alzheimer’s disease psychosis study remains on track for August to October 2026 timeframe. Accelerated enrollment in the trofinetide clinical trial in Japan, with topline results now anticipated in the September to November 2026 timeframe. Delphi expert consensus panel recently recommended DAYBUE as part of the standard of care for eligible patients with Rett syndrome.1 Financial Results
Revenues
GAAP total revenues, comprised of net product sales from NUPLAZID and DAYBUE, were $268 million for the first quarter of 2026, up 10% as compared to GAAP total revenues of $244 million in the first quarter of 2025, and up 11% as compared to non-GAAP adjusted total revenues of $242 million in the first quarter of 2025.
GAAP net product sales of NUPLAZID were $167 million for the first quarter of 2026, up 5% compared to GAAP net product sales of $160 million for the first quarter of 2025, and up 6% as compared to non-GAAP adjusted net product sales of $157 million for the first quarter of 2025.
Net product sales of DAYBUE were $101 million for the first quarter of 2026, an increase of 20% as compared to $85 million for the first quarter of 2025.
A reconciliation of NUPLAZID non‑GAAP adjusted net sales and non‑GAAP adjusted total revenues is provided in Table 1. A description of these adjustments is included under ‘Non-GAAP Financial Measures.’
Research and Development
Research and development expenses for the first quarter of 2026 were $77 million, compared to $78 million for the same period of 2025.
Selling, General and Administrative
Selling, general and administrative expenses for the first quarter of 2026 were $171 million, compared to $126 million for the same period of 2025. The increase in selling, general and administrative expenses during the first quarter was primarily driven by increased investments to support continued growth of NUPLAZID and DAYBUE.
Net Income
For the first quarter of 2026, Acadia reported net income of $4 million, or $0.02 per diluted share, compared to a net income of $19 million, or $0.11 per diluted share, for the same period in 2025.
Cash and Investments
At March 31, 2026, Acadia’s cash, cash equivalents, and investment securities totaled $851 million, compared to $820 million at December 31, 2025.
Full Year 2026 Financial Guidance (GAAP):
Acadia is reaffirming its 2026 guidance as first provided on February 25, 2026:
Total revenues in the range of $1.22 to $1.28 billion. NUPLAZID net product sales in the range of $760 to $790 million. DAYBUE net product sales in the range of $460 to $490 million. R&D expense in the range of $385 to $410 million. SG&A expense in the range of $660 to $700 million. Conference Call and Webcast Information
Acadia will host a conference call to discuss the first quarter 2026 results today, Wednesday, May 6, 2026 at 1:30 p.m. PT/4:30 p.m. ET. The conference call may be accessed by registering for the call here. Once registered, participants will receive an email with the dial-in number and unique PIN number to use for accessing the call.
About NUPLAZID® (pimavanserin)
Pimavanserin is a selective serotonin inverse agonist and antagonist preferentially targeting 5-HT2A receptors. These receptors are thought to play an important role in neuropsychiatric disorders. In vitro, pimavanserin demonstrated no appreciable binding affinity for dopamine (including D2), histamine, muscarinic, or adrenergic receptors. Pimavanserin was approved for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis by the U.S. Food and Drug Administration in April 2016 under the trade name NUPLAZID.
About DAYBUE® (trofinetide)
Trofinetide is a synthetic version of a naturally occurring molecule known as the tripeptide glycine-proline-glutamate (GPE). The mechanism by which trofinetide exerts therapeutic effects in patients with Rett syndrome is unknown. Trofinetide was approved for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older by the U.S. Food and Drug Administration in March 2023 under the trade name DAYBUE or DAYBUE STIX.
About Acadia Pharmaceuticals
Acadia is committed to turning scientific promise into meaningful innovation that makes the difference for underserved neurological and rare disease communities around the world. Our commercial portfolio includes the first and only FDA-approved treatments for Parkinson’s disease psychosis and Rett syndrome. We are developing the next wave of therapeutic advancements with a robust and diverse pipeline that includes mid- to late-stage programs in Alzheimer’s disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. At Acadia, we’re here to be their difference. For more information, visit us at acadia.com and follow us on LinkedIn and X.
Non-GAAP Financial Measures
This press release contains the following financial measures that do not comply with U.S. generally accepted accounting principles (GAAP): non-GAAP adjusted net sales for NUPLAZID for the first quarter of 2025 and non-GAAP adjusted total revenues for the first quarter of 2025. In preparing these non-GAAP financial results, the Company includes adjustments made to reflect the impact of a change in estimate related to NUPLAZID IRA rebate accruals. Please refer to our press release dated February 25, 2026, for additional details. These non-GAAP financial measures complement GAAP results and are used by management to analyze financial performance and evaluate period-to-period changes. Management believes these non-GAAP financial measures are useful to investors and other users of the Company’s financial statements to facilitate period-to-period comparability. These non-GAAP financial measures are not meant to be considered as a substitute for comparable GAAP measures; should be read in conjunction with the Company’s consolidated financial statements prepared in accordance with GAAP; have no standardized meaning prescribed by GAAP; and are unlikely to be comparable with non-GAAP disclosures released by other companies.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements other than statements of historical fact and can be identified by terms such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “projects,” “predicts,” “potential,” “guidance,” “continue” and similar expressions (including the negative thereof) intended to identify forward-looking statements. Forward-looking statements contained in this press release, include, but are not limited to, statements about: (i) our business strategy, objectives and opportunities, including support for and innovations in our pipeline assets and business development opportunities, DAYBUE sales growth, interest in DAYBUE STIX, and potential for enhanced shareholder value; (ii) plans for, including timing, development and progress of commercialization or regulatory timelines for our products, including NUPLAZID and DAYBUE, and our product candidates; (iii) benefits to be derived from and efficacy of our products, including the potential advantages of our products; (iv) the timing and conduct of our clinical trials; and (v) our estimates regarding our future financial performance, profitability, capital requirements or expenses, including our full year 2026 financial guidance. Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. Such risks, uncertainties and other factors include, but are not limited to: our dependency on the continued successful commercialization of our products and our ability to maintain or increase sales of our products; our plans to continue commercial growth; the costs of our commercialization plans and development programs, and the financial impact or revenues from any commercialization we undertake; our ability to obtain necessary regulatory approvals for our product candidates and, if and when approved, market acceptance of our products; the risks associated with clinical trials and their outcomes, including risks of unsuccessful enrollment and negative or inconsistent results; our dependence on third-party collaborators, clinical research organizations, manufacturers, suppliers and distributors; the impact of competitive products and therapies; our ability to generate or obtain the necessary capital to fund our operations; our ability to grow, equip and train our specialized sales forces; our ability to manage the growth and complexity of our organization; our ability to maintain, protect and enhance our intellectual property; and our ability to continue to stay in compliance with applicable laws and regulations. Given the risks and uncertainties, you should not place undue reliance on these forward-looking statements. For a discussion of these and other risks, uncertainties and other factors that may cause our actual results, performance or achievements to differ, please refer to our annual report on Form 10-K for the year ended December 31, 2025 as well as our subsequent filings with the Securities and Exchange Commission from time to time. The forward-looking statements contained herein are made as of the date hereof, and we undertake no obligation to update them after this date, except as required by law.
ACADIA PHARMACEUTICALS INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts)
(Unaudited)
Three Months Ended March 31,
2026
2025
Revenues
Product sales, net
$
268,062
$
244,317
Total revenues
268,062
244,317
Operating expenses
Cost of product sales (1)(2)
24,791
20,392
Research and development (2)
76,868
78,265
Selling, general and administrative (2)
171,019
126,370
Total operating expenses
272,678
225,027
(Loss) income from operations
(4,616
)
19,290
Interest income, net
8,055
7,901
Other income
542
588
Income before income taxes
3,981
27,779
Income tax expense
344
8,792
Net income
$
3,637
$
18,987
Earnings per share:
Basic
$
0.02
$
0.11
Diluted
$
0.02
$
0.11
Weighted average common shares outstanding:
Basic
170,517
166,808
Diluted
172,706
167,668
(1) Includes license fees and royalties
(2) Includes the following stock-based compensation expense
Cost of product sales
$
328
$
334
Research and development
$
4,142
$
3,433
Selling, general and administrative
$
10,228
$
7,613
ACADIA PHARMACEUTICALS INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
(Unaudited)
March 31,
2026
December 31,
2025
(unaudited)
Assets
Cash, cash equivalents and investment securities
$
851,458
$
819,686
Accounts receivable, net
135,350
121,457
Interest and other receivables
13,034
26,774
Inventory
31,574
34,670
Prepaid expenses
64,600
59,526
Total current assets
1,096,016
1,062,113
Property and equipment, net
14,652
7,511
Operating lease right-of-use assets
46,274
47,354
Intangible assets, net
106,171
108,893
Restricted cash
7,846
7,845
Long-term inventory
80,719
76,704
Deferred tax assets
249,624
249,879
Other assets
3,928
3,896
Total assets
$
1,605,230
$
1,564,195
Liabilities and stockholders’ equity
Accounts payable
$
12,246
$
10,903
Accrued liabilities
293,278
266,211
Total current liabilities
305,524
277,114
Operating lease liabilities
39,003
40,554
Other long-term liabilities
12,637
19,137
Total liabilities
357,164
336,805
Total stockholders’ equity
1,248,066
1,227,390
Total liabilities and stockholders’ equity
$
1,605,230
$
1,564,195
Table 1. ACADIA PHARMACEUTICALS INC.
NON-GAAP RECONCILIATION
(in millions)
(Unaudited)
1Q25
1Q26
GAAP NUPLAZID Net Sales
$
159.7
$
166.9
Allocation of 2025 Amount
$
(2.3
)
$
—
Non-GAAP Adjusted NUPLAZID Net Sales
$
157.4
$
166.9
DAYBUE Net Sales
$
84.6
$
101.2
Non-GAAP Adjusted Total Revenues
$
242.0
$
268.1
References
Prange EO, Beisang A, Pehlivan D, et al. Expert Consensus on Real-World Use of Trofinetide for Rett Syndrome Using a Modified Delphi Method. Ann Child Neurol. 2026; 4:38-51. More News From Acadia Pharmaceuticals Inc.
Acadia Pharmaceuticals (ACAD - Free Report) came out with quarterly earnings of $0.02 per share, missing the Zacks Consensus Estimate of $0.04 per share. This compares to earnings of $0.11 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -54.23%. A quarter ago, it was expected that this drugmaker would post earnings of $0.12 per share when it actually produced earnings of $0.16, delivering a surprise of +33.33%.
Over the last four quarters, the company has surpassed consensus EPS estimates three times.
Acadia, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $268.06 million for the quarter ended March 2026, missing the Zacks Consensus Estimate by 5%. This compares to year-ago revenues of $244.32 million. The company has topped consensus revenue estimates two times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Acadia shares have lost about 16.3% since the beginning of the year versus the S&P 500's gain of 6%.
What's Next for Acadia?While Acadia has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Acadia was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.11 on $305.7 million in revenues for the coming quarter and $0.45 on $1.25 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the bottom 40% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
BioHarvest Sciences Inc. (BHST - Free Report) , another stock in the same industry, has yet to report results for the quarter ended March 2026. The results are expected to be released on May 14.
This company is expected to post quarterly loss of $0.13 per share in its upcoming report, which represents no change from the year-ago quarter. The consensus EPS estimate for the quarter has been revised 9.1% higher over the last 30 days to the current level.
BioHarvest Sciences Inc.'s revenues are expected to be $8.51 million, up 8.2% from the year-ago quarter.
Key Takeaways Acadia reported Q1 EPS of 2 cents and revenues of $268.1M, both below consensus estimates.ACAD posted 10% total revenue growth as Daybue sales rose 20% and Nuplazid sales increased 5%.Acadia reaffirmed 2026 sales guidance of $1.22-$1.28B despite the Q1 revenue miss. Acadia Pharmaceuticals (ACAD - Free Report) reported first-quarter 2026 earnings per share (EPS) of 2 cents, which missed the Zacks Consensus Estimate of 4 cents. In the year-ago quarter, the company had reported EPS of 11 cents.
In the first quarter, Acadia recorded total revenues of $268.1 million, which missed the Zacks Consensus Estimate of $282 million. ACAD’s net product revenues comprise sales of its two marketed products, Nuplazid (pimavanserin) and Daybue (trofinetide).
Acadia’s first drug, Nuplazid, is approved in the United States for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. ACAD’s second product, Daybue, received approval in 2023 for treating Rett syndrome in adult and pediatric patients aged two years and older. The drug was launched in the United States in April 2023.
Total revenues increased 10% year over year, driven by contributions from Daybue and continued growth in Nuplazid's market share.
Year to date, Acadia shares have plunged 19.6% compared with the industry’s 1.6% decline.
Image Source: Zacks Investment Research
ACAD’s Q1 Earnings in DetailRevenues from Nuplazid increased 5% year over year to $167 million in the first quarter of 2026, driven primarily by volume growth. Nuplazid sales missed the Zacks Consensus Estimate of $179.7 million.
Daybue recorded net product sales of $101 million in the reported quarter, up 20% year over year, driven by the growth in the drug’s unit sales as Acadia shipped to more unique patients. The reported figure, however, missed the Zacks Consensus Estimate of $105.6 million.
Research and development (R&D) expenses were $76.9 million, down 2% year over year.
Selling, general and administrative (SG&A) expenses were $171 million, up 35% year over year, due to increased marketing investments to support the continued growth of Nuplazid and Daybue.
Acadia had cash, cash equivalents and investments worth $851 million as of March 31, 2026, compared with $820 million as of Dec. 31, 2025.
ACAD Reaffirms 2026 Financial OutlookAcadia continues to expect total revenues from the U.S. sales of its products to be in the range of $1.22-$1.28 billion in 2026. Nuplazid net product sales are expected to be in the range of $760-$790 million, while U.S. sales of Daybue are expected to be between $460 million and $490 million.
R&D expenses in 2026 are projected to be in the range of $385-$410 million, while SG&A expenses are expected to be between $660 million and $700 million.
ACAD's Recent Pipeline UpdatesIn early March, Acadia announced that the advisory committee to the regulatory body in the EU had formally adopted a negative opinion recommending against the approval of trofinetide for the treatment of Rett syndrome in patients aged two years and older.
The decision was expected as the advisory committee had informed ACAD of a negative trend vote on its marketing application for trofinetide to treat Rett syndrome in February. Following the formal adoption of the opinion, Acadia reviewed the grounds for refusal in detail and plans to request a re-examination. The regulatory setback has delayed the potential approval of trofinetide in the EU.
In late 2025, the FDA approved Daybue Stix (trofinetide) for oral solution, a dye- and preservative-free powder formulation for the treatment of Rett syndrome in adults and pediatric patients aged two years and older. The new product expands the Daybue franchise, which remains the only FDA-approved treatment option for this indication.
Per Acadia, the full U.S. launch of Daybue STIX is underway, with nearly 30% of patients using STIX either new to treatment or resuming therapy after previously discontinuing the liquid formulation. The company will continue to offer both formulations in the United States, strengthening its positioning in the Rett syndrome treatment market.
Acadia also anticipates a data readout from the phase II RADIANT study of ACP-204 (remlifanserin) for Alzheimer’s disease psychosis, which is on track for the August to October 2026 timeframe and represents a potential catalyst for the company this year.
ACAD's Zacks Rank & Stocks to ConsiderAcadia currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Catalyst Pharmaceuticals (CPRX - Free Report) , Immatics (IMTX - Free Report) and Inovio Pharmaceuticals (INO - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Over the past 60 days, estimates for Catalyst Pharmaceuticals’ 2026 EPS have declined from $2.82 to $2.79. CPRX shares have gained 30.8% year to date.
Catalyst Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 35.19%.
Over the past 60 days, estimates for Immatics’ 2026 loss per share have narrowed from $1.61 to $1.49. IMTX shares have gained 9.6% year to date.
Immatics’ earnings beat estimates in three of the trailing four quarters and missed on the remaining occasion, delivering an average negative surprise of 8.06%.
Over the past 60 days, estimates for Inovio Pharmaceuticals’ 2026 loss per share have narrowed from $1.26 to $1.06. INO shares have plunged 28.8% year to date.
Inovio Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 57.94%.
CocaCola (NYSE:KO) EVP Jennifer Mann Sells 23,984 SharesMarketBeat
CocaCola Company (The) (NYSE:KO - Get Free Report) EVP Jennifer Mann sold 23,984 shares of the firm's stock in a transaction dated Wednesday, June 10th. The stock was sold at an average price of $83.41, for a total value of $2,000,505.44. Following the completion of the transaction, the executive vice president owned 157,400 shares of the company's stock, valued at approximately $13,128,734. The trade was a 13.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
NYSE:KO
Read CocaCola (NYSE:KO) EVP Jennifer Mann Sells 23,984 Shares
2 hours ago
Dutch Bros (NYSE:BROS) Major Shareholder Sells $15,759,829.98 in StockMarketBeat
Dutch Bros Inc. (NYSE:BROS - Get Free Report) major shareholder Dm Individual Aggregator, Llc sold 261,054 shares of the company's stock in a transaction dated Wednesday, June 10th. The stock was sold at an average price of $60.37, for a total transaction of $15,759,829.98. Following the completion of the sale, the insider owned 2,671,855 shares in the company, valued at $161,299,886.35. This represents a 8.90% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Large shareholders that own at least 10% of a company's shares are required to disclose their transactions with the SEC.
NYSE:BROS
Read Dutch Bros (NYSE:BROS) Major Shareholder Sells $15,759,829.98 in Stock
2 hours ago
Insider Selling: Dutch Bros (NYSE:BROS) Major Shareholder Sells 261,055 Shares of StockMarketBeat
Dutch Bros Inc. (NYSE:BROS - Get Free Report) major shareholder Dm Individual Aggregator, Llc sold 261,055 shares of the business's stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $63.02, for a total value of $16,451,686.10. Following the completion of the transaction, the insider owned 2,410,800 shares in the company, valued at approximately $151,928,616. This trade represents a 9.77% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Large shareholders that own at least 10% of a company's shares are required to disclose their transactions with the SEC.
NYSE:BROS
Read Insider Selling: Dutch Bros (NYSE:BROS) Major Shareholder Sells 261,055 Shares of Stock
2 hours ago
Travis Boersma Sells 749,999 Shares of Dutch Bros (NYSE:BROS) StockMarketBeat
Dutch Bros Inc. (NYSE:BROS - Get Free Report) Chairman Travis Boersma sold 749,999 shares of Dutch Bros stock in a transaction that occurred on Wednesday, June 10th. The stock was sold at an average price of $60.39, for a total transaction of $45,292,439.61. Following the completion of the sale, the chairman owned 2,671,855 shares of the company's stock, valued at $161,353,323.45. This represents a 21.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Dutch Bros Inc. (NYSE:BROS - Get Free Report) Chairman Travis Boersma sold 750,000 shares of the company's stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $63.02, for a total value of $47,265,000.00. Following the sale, the chairman owned 2,410,800 shares in the company, valued at approximately $151,928,616. This trade represents a 23.73% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Acadia Pharmaceuticals: A Mid-Cap Biotech Making Large MovesACADIA Pharmaceuticals NASDAQ: ACAD executives used an RBC Capital Markets investor session to outline the company’s clinical rationale for remlifanserin in Alzheimer’s disease psychosis, provide updates on commercial trends for NUPLAZID and DAYBUE, and discuss selected pipeline and business development priorities.
The discussion, hosted by RBC Capital Markets analyst Nevin Varghese, featured ACADIA executives including Sanjeev Pathak, senior vice president and head of clinical development, and Tom Garner, chief commercial officer.
Get ACADIA Pharmaceuticals alerts:
Remlifanserin Program Focuses on Higher Exposure and Trial Design Pathak said the key distinction between remlifanserin and pimavanserin is ACADIA’s effort to eliminate or mitigate QTc prolongation concerns. He said non-clinical data, in vitro studies and emerging clinical observations have supported that view, potentially allowing ACADIA to test higher doses and exposures.
“What it allows us to do is increase the dose, increase the exposures,” Pathak said. He added that ACADIA’s prior pimavanserin work suggested higher average blood levels were associated with stronger efficacy.
Pathak said the remlifanserin program includes two doses: 30 milligrams, which he described as equivalent to pimavanserin 34 milligrams or the NUPLAZID dose, and 60 milligrams, which is intended to provide higher exposure. He also noted that remlifanserin has a shorter half-life than pimavanserin, reaching steady state in roughly five to six days in elderly patients, compared with 12 to 15 days for pimavanserin.
In Alzheimer’s disease psychosis, Pathak said ACADIA is applying several lessons from its earlier pimavanserin experience. Those include running a dedicated program with multiple studies, enriching for patients with more severe psychosis, and using what the company considers a more sensitive endpoint, SAPS-H+D.
Asked about trial conduct and placebo response, Pathak said ACADIA is using experienced staff from the pimavanserin program, emphasizing site selection, investigator training, blinded monitoring and biomarker confirmation of Alzheimer’s disease. He said the company is seeking to reduce patient heterogeneity and exclude patients whose symptoms may resemble Alzheimer’s disease psychosis but arise from other psychiatric causes.
Pathak said the current study is powered at 80% for a moderate standardized effect size of 0.4. He said the goal is to generate data that can inform and enrich potential Phase 3 development. While acknowledging that effect sizes can shrink from Phase 2 to Phase 3, he said ACADIA hopes to use Phase 2 learnings to refine the Phase 3 population and biomarkers, depending on the data.
NUPLAZID Sales Force Expansion Still in Early Stages Garner said ACADIA expanded its NUPLAZID sales team in the first quarter, increasing overall reach by about 30%. He said the company now covers roughly 10,000 customers, with neurologists representing about 45% of that group and remaining a primary focus.
Garner said ACADIA has seen a shift in the mix of NUPLAZID prescribers over the past two years, helped by direct-to-consumer and healthcare professional outreach. In the first quarter, he said about 25% of total writers were new-to-brand writers.
However, Garner cautioned that it remains early to judge the full impact of the sales force expansion. The expanded team was fully trained and in the field around the middle of the first quarter, and ACADIA expects a six- to nine-month ramp before the model reaches full efficiency. He said the company expects the impact to be more weighted toward the back half of the year.
Garner also addressed refill delays seen in the first quarter, saying the company did not identify a specific underlying issue. He attributed the disruption to a larger-than-usual group of patients returning late, noting that NUPLAZID has high Medicare exposure, with roughly 80% of patients on Medicare. He said the company does not expect the issue to create a continuing drag through the rest of the year.
DAYBUE STIX Launch Aims to Support Persistence and Reengagement Garner said ACADIA’s DAYBUE strategy has expanded beyond Rett syndrome Centers of Excellence into community settings. He said about two-thirds of Rett patients fall outside direct care at a Center of Excellence, and ACADIA remains under-penetrated in that segment, in the late-20% range.
On persistence, Garner said ACADIA is seeing a growing base of patients remaining on therapy as more cohorts move through 12 and 18 months. He said 12-month persistence across cohorts is north of 50%, close to 55%, while 18-month persistence is in the 50% range.
Garner said the launch of DAYBUE STIX in the first quarter could help support additional growth and longer treatment duration. The product is a powder formulation that can be mixed with non-dairy liquids, requires no refrigeration and is more portable than the liquid formulation. He said ACADIA has removed many excipients that had been a concern for some patients and caregivers.
Initial demand has come from treatment-naive patients, returning patients and patients considering a switch from liquid DAYBUE, Garner said. He added that feedback from caregivers and healthcare professionals has been positive, particularly because the formulation responds to concerns raised about the liquid product.
Garner said ACADIA amplified its direct-to-consumer efforts in April after the initial Centers of Excellence-focused launch. He said the company’s Family Support Educators have also been reengaging families, including those who discontinued therapy because of formulation concerns.
European Review and Pipeline Updates Pathak said the reexamination process for DAYBUE in the European Union is structured and time-bound, with ACADIA expecting it to conclude by the end of June. He said rapporteurs have been assigned, the company has submitted its grounds for reexamination and ACADIA is preparing for both a Scientific Advisory Group meeting and an oral reexamination.
Pathak also discussed ACP-271, ACADIA’s GPR88 agonist, saying the company is excited by the program’s potential in movement disorders and associated neuropsychiatric symptoms. He said GPR88 is abundant in motor areas of the brain and present at lower density in areas tied to higher cognitive function. ACADIA has seen consistent non-clinical benefit in animal models, including tardive dyskinesia models, without typical safety findings such as sedation, according to Pathak.
On business development, a company representative said ACADIA continues to take a “barbell” approach, looking at both neuroscience and rare disease opportunities. The company is interested in late-stage assets that could launch within the next several years, as well as earlier-stage assets that could supplement its early-stage portfolio.
About ACADIA Pharmaceuticals NASDAQ: ACADACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA's research centers concentrate on conditions with significant unmet medical needs, including Parkinson's disease psychosis, Alzheimer's disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.
The company's flagship product, NUPLAZID® (pimavanserin), received U.S.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Should You Invest $1,000 in ACADIA Pharmaceuticals Right Now?Before you consider ACADIA Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ACADIA Pharmaceuticals wasn't on the list.
While ACADIA Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
It has been about a month since the last earnings report for Acadia Pharmaceuticals (ACAD - Free Report) . Shares have lost about 3.7% in that time frame, underperforming the S&P 500.
But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is Acadia due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.
ACAD Q1 Earnings & Revenues Miss Estimates Despite Y/Y Sales GrowthAcadiareported first-quarter 2026 earnings per share (EPS) of 2 cents, which missed the Zacks Consensus Estimate of 4 cents. In the year-ago quarter, the company had reported EPS of 11 cents.
In the first quarter, Acadia recorded total revenues of $268.1 million, which missed the Zacks Consensus Estimate of $282 million. ACAD’s net product revenues comprise sales of its two marketed products, Nuplazid (pimavanserin) and Daybue (trofinetide).
Total revenues increased 10% year over year, driven by contributions from Daybue and continued growth in Nuplazid's market share.
ACAD’s Q1 Earnings in DetailRevenues from Nuplazid increased 5% year over year to $167 million in the first quarter of 2026, driven primarily by volume growth. Nuplazid sales missed the Zacks Consensus Estimate of $179.7 million.
Daybue recorded net product sales of $101 million in the reported quarter, up 20% year over year, driven by the growth in the drug’s unit sales as Acadia shipped to more unique patients. The reported figure, however, missed the Zacks Consensus Estimate of $105.6 million.
Research and development (R&D) expenses were $76.9 million, down 2% year over year.
Selling, general and administrative (SG&A) expenses were $171 million, up 35% year over year, due to increased marketing investments to support the continued growth of Nuplazid and Daybue.
Acadia had cash, cash equivalents and investments worth $851 million as of March 31, 2026, compared with $820 million as of Dec. 31, 2025.
ACAD Reaffirms 2026 Financial OutlookAcadia continues to expect total revenues from the U.S. sales of its products to be in the range of $1.22-$1.28 billion in 2026. Nuplazid net product sales are expected to be in the range of $760-$790 million, while U.S. sales of Daybue are expected to be between $460 million and $490 million.
R&D expenses in 2026 are projected to be in the range of $385-$410 million, while SG&A expenses are expected to be between $660 million and $700 million.
How Have Estimates Been Moving Since Then?It turns out, fresh estimates have trended downward during the past month.
The consensus estimate has shifted -46.15% due to these changes.
VGM ScoresAt this time, Acadia has a average Growth Score of C, though it is lagging a lot on the Momentum Score front with an F. However, the stock has a score of C on the value side, putting it in the middle 20% for value investors.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
OutlookEstimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. It's no surprise Acadia has a Zacks Rank #4 (Sell). We expect a below average return from the stock in the next few months.
Performance of an Industry PlayerAcadia is part of the Zacks Medical - Biomedical and Genetics industry. Over the past month, Vertex Pharmaceuticals (VRTX - Free Report) , a stock from the same industry, has gained 3.9%. The company reported its results for the quarter ended March 2026 more than a month ago.
Vertex reported revenues of $2.99 billion in the last reported quarter, representing a year-over-year change of +7.8%. EPS of $4.47 for the same period compares with $4.06 a year ago.
Vertex is expected to post earnings of $4.79 per share for the current quarter, representing a year-over-year change of +6%. Over the last 30 days, the Zacks Consensus Estimate has changed -0.6%.
The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Vertex. Also, the stock has a VGM Score of C.
